Omeprazole Olpha

Omeprazole, the active ingredient in Omeprazole Olpha, is a Proton Pump Inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Omeprazole Olpha as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Olpha is a proton pump inhibitor that acts on gastric acid secretion pathways. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosions caused by chronic acid exposure. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

Omeprazole Olpha may cause a range of adverse reactions. Most are mild and resolve after continued therapy.

Common Side Effects: - Headache: mild, transient headache. - Diarrhoea: loose stools, usually self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Acute interstitial nephritis: kidney inflammation that may cause reduced urine output. - Hypomagnesemia: low magnesium levels leading to muscle cramps or arrhythmia. - Stevens‑Johnson syndrome: rare skin blistering disorder. - Fracture risk: increased likelihood of hip, wrist or vertebral fractures with long‑term use.

When prescribing Omeprazole Olpha, clinicians should consider several safety aspects: - Assess renal function: adjust use in patients with severe renal impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Evaluate long‑term need: limit duration to the shortest effective period to reduce fracture risk. - Monitor electrolytes: check magnesium levels during prolonged therapy. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole Olpha can affect the pharmacokinetics of several concomitant medicines. Awareness of key interactions helps maintain therapeutic effectiveness.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activity, increasing cardiovascular event risk. - Atazanavir: markedly decreased antiviral exposure, compromising HIV treatment. - Dasatinib: lowered plasma concentrations, reducing anticancer efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent coagulation monitoring. - Phenytoin: possible reduction in phenytoin levels, necessitating dose adjustment. - Digoxin: slight increase in serum digoxin, warranting periodic level checks.